Nowadays, ICIs, especially those targeting PD-1 and PD-L1, have been approved for the treatment of various cancers.23–25,405 Great success has been achieved in some solid tumors such as lung cancer and melanoma.405,406 Nevertheless, ICIs are limited by the fact that only about one-third of patients respond to ICIs. The gene discussed is CD274; the disease is cancer.